GaiaCell develops exosome platforms as a cell-independent biological approach intended for regenerative and supportive clinical applications, where the combination of biological activity, safety, and practical clinical usability is essential.
Development is focused on applications that leverage natural cellular signaling mechanisms without the direct use of living cells, opening new opportunities for a wide range of regenerative interventions.
Exosomes are small extracellular vesicles secreted by cells that participate in intercellular communication by transferring biologically active molecules, including proteins, lipids, and nucleic acids. Due to their natural role in signaling and regulation of cellular processes, exosomes represent an attractive basis for the development of biological approaches aimed at supporting regeneration, tissue repair, and functional improvement.
Although highly effective, classical cell therapies often involve:
Exosomes enable an alternative approach that preserves key biological effects of cell therapies while reducing complexity and increasing flexibility in clinical application.
Rather than developing a single product, we are building a scalable exosome platform that allows adaptation to various clinical needs and applications. Exosome development at GaiaCell is based on a platform approach that includes:
Development of exosome platforms is primarily focused on regenerative and supportive applications, with emphasis on:
Such applications are particularly suitable for use in specialized clinical environments where safety, reproducibility, and predictable clinical outcomes are essential.
Exosome-based approaches enable:
Due to these characteristics, exosomes represent an important long-term development pillar with clear clinical and partnership potential.
The GaiaCell exosome program is developed within a research and translational framework, with a focus on validating biological activity, understanding mechanisms of action, and identifying clinically relevant applications. Details regarding source cells, isolation processes, and functional properties remain part of a protected development environment and are subject to professional discussion within collaborations.
TIL therapies represent a natural complement to GaiaCell’s CAR-T and exosome development programs. Together, they form a comprehensive portfolio of advanced cell and cell-derived therapeutic platforms designed for diverse clinical challenges and indications.
GaiaCell seeks collaborations in the areas of:
We build partnerships based on professional dialogue, a shared vision, and a long-term understanding of the clinical potential of exosome-based approaches.